GSK-2849466
 | |
| Clinical data | |
|---|---|
| Drug class | Selective androgen receptor modulator |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| UNII | |
| Chemical and physical data | |
| Formula | C12H14Cl2N2O |
| Molar mass | 273.16 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
GSK-2849466 is an investigational new drug that is a selective androgen receptor modulator (SARM) that was being developed by GlaxoSmithKline (GSK). This experimental compound reached Phase I clinical trials for the treatment of cachexia and heart failure.[1][2][3] However, as of February 2014, GSK discontinued the development of GSK-2849466 for both indications after completing Phase I studies.[2]
References
[edit]- ^ "GSK-2849466". PatSnap.
- ^ a b "GSK 2849466". AdisInsight. Springer Nature Switzerland AG. Archived from the original on 2024-01-14. Retrieved 2024-01-14.
- ^ Fonseca GW, Dworatzek E, Ebner N, Von Haehling S (August 2020). "Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials". Expert Opinion on Investigational Drugs. 29 (8): 881–891. doi:10.1080/13543784.2020.1777275. PMID 32476495.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |